| Literature DB >> 34868390 |
Jiangbiao Xiong1, Shujiao Yu1, Ren Liu1, Xia Fang1, Rui Wu1.
Abstract
OBJECTIVE: To explore the role of conjunctival microvasculation combined with echocardiography in evaluating the prognosis of pulmonary arterial hypertension in systemic lupus erythematosus (SLE-PAH).Entities:
Mesh:
Year: 2021 PMID: 34868390 PMCID: PMC8642014 DOI: 10.1155/2021/2135942
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Comparisons of the characteristics between SLE-PAH patients and SLE patients without PAH.
| Characteristics | SLE-PAH ( | SLE without PAH ( |
|
|---|---|---|---|
| Female sex, | 15 (88%) | 31 (91%) | 0.625 |
| Age, years ± SD | 44.4 ± 14.6 | 41.7 ± 12.9 | 0.751 |
| Pleural effusion, | 2 (6.7%) | 7 (4.7%) | 0.646 |
| Raynaud's phenomenon, | 17 (56.7%) | 48 (32.0%) | 0.010∗ |
| Oral ulcer, | 4 (13.3%) | 26 (17.3%) | 0.592 |
| Alopecia, | 8 (26.7%) | 66 (44.0%) | 0.078 |
| Rash, | 9 (30.0%) | 50 (33.3%) | 0.723 |
| Pericardial effusion, | 6 (20.0%) | 2 (1.3%) | ≈0.00∗ |
| Lupus nephritis, | 5 (16.7%) | 30 (20.0%) | 0.674 |
| Cytopenia, | 3 (10.0%) | 6 (4.0%) | 0.169 |
| Elevated ESR, | 19 (63.3%) | 80 (53.3%) | 0.315 |
| Low C3, | 26 (86.7%) | 114 (76.0%) | 0.200 |
| Low C4, | 23 (76.7%) | 103 (68.7%) | 0.383 |
| Anti-dsDNA antibody, | 18 (60.0%) | 62 (41.3%) | 0.060 |
| LA, | 24 (80.0%) | 66 (44.0%) | ≈0.00∗ |
| ACA, | 17 (56.7%) | 13 (8.7%) | ≈0.00∗ |
| Conjunctival microvasculation | |||
| Ischemic areas, | 6 (35.3%) | 5 (14.7%) | 0.042∗ |
| Reticulum deformity, | 4 (23.5%) | 13 (38.2) | 0.233 |
| Microangioma, | 8 (47.1%) | 7 (41.2) | 0.101 |
| Twisting, | 16 (94.1%) | 27 (79.4) | 0.242 |
| Dilation, | 8 (47.1%) | 24 (70.6) | 0.131 |
| Wound spot, | 13 (76.5) | 17 (50) | 0.081 |
| Hemorrhage, | 5 (29.4%) | 6 (17.6) | 0.472 |
SD: standard deviation; ESR: erythrocyte sedimentation rate; LA: lupus anticoagulant; ACA: anticardiolipin antibodies. ∗P < 0.05.
Correlation between VD and MFI of conjunctival microvasculation and SLE-PAH-related parameters.
| sPAP | NT-proBNP | 6MWD | SUA | RDW | RAP | TAPSE | |||
|---|---|---|---|---|---|---|---|---|---|
| Spearman's rho | VD | Correlation coefficient | -0.441 | -0.528∗ | 0.574∗ | -0.560∗ | -0.323 | -0.637∗∗ | 0.539∗ |
| Sig. (2-tailed) | 0.076 | 0.029 | 0.016 | 0.019 | 0.306 | 0.006 | 0.026 | ||
| MFI | Correlation coefficient | -0.537∗ | -0.546∗ | 0.504∗ | -0.350 | -0.305 | -0.689∗∗ | 0.683∗∗ | |
| Sig. (2-tailed) | 0.026 | 0.023 | 0.039 | 0.168 | 0.335 | 0.002 | 0.003 | ||
VD: vessel density; MFI: microvascular flow index; sPAP: systolic pulmonary artery pressure; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; 6MWD: 6-minute walking distance; SUA: serum uric acid; RDW: red blood cell volume distribution width; RAP: right atrial pressure; TAPSE: tricuspid annular plane systolic excursion. ∗P < 0.05, ∗∗P < 0.01.
Figure 1Scatter plot of the correlation analysis of VD, MFI, 6MWD, and TAPSE.
Comparison of the parameters between different risk groups.
| Parameters | Low risk ( | Intermediate risk ( | High risk ( |
|
|---|---|---|---|---|
| sPAP (mmHg) | 32.0 ± 8.0 | 59.8 ± 31.2 | 61.5 ± 9.2 | 0.23 |
| TAPSE (cm) | 2.7 ± 0.1 | 2.1 ± 0.4 | 1.4 ± 0.3 | 0.012∗ |
| RAP (mmHg) | 5.8 ± 1.5 | 8.2 ± 3.7 | 15 ± 0 | 0.147 |
| NT-proBNP (pg/mL) | 247.8 ± 250.1 | 1456.5 ± 719.8 | 5418.5 ± 2617 | 0.003∗ |
| SUA (ummol/L) | 430.8 ± 117.9 | 436.7 ± 92.3 | 518.5 ± 89.8 | 0.67 |
| RDW (%) | 15.4 ± 2.3 | 21.7 ± 10.2 | 18.5 ± 1.7 | 0.315 |
| VD (n/mm2) | 2.7 ± 0.3 | 2.3 ± 0.2 | 1.7 ± 0.4 | 0.006∗ |
| MFI | 2.8 ± 0.4 | 2.3 ± 0.3 | 1.5 ± 0.7 | 0.019∗ |
| Conjunctival microvascular changes |
|
|
|
sPAP: systolic pulmonary artery pressure; TAPSE: tricuspid annular plane systolic excursion; RAP: right atrial pressure; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; SUA: serum uric acid; RDW: red blood cell volume distribution width; VD: vessel density; MFI: microvascular flow index. ∗P < 0.05. △ Kruscal-Wallis test; # ischemic areas; ⟶ microangioma.
Figure 2Discriminant analysis of the echocardiography combined with VD and MFI in three groups of patients with different risk stratifications.